...
首页> 外文期刊>Oxford Medical Case Reports >Advanced primary nonurachal adenocarcinoma of urinary bladder responding to modified FOLFOX6 and capecitabine: a case report
【24h】

Advanced primary nonurachal adenocarcinoma of urinary bladder responding to modified FOLFOX6 and capecitabine: a case report

机译:先进的原发性膀胱腺癌响应改性Folfox6和Capecitabine:案例报告

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Careful morphology and immunohistochemistry study can make an accurate differential diagnosis of primary adenocarcinoma of urinary bladder from metastatic lesions involving bladder, especially cancer arising in colon, but there is yet no consensus regarding the standard chemotherapy for advanced adenocarcinoma of urinary bladder among medical oncologists. Sustained response to modified FOLFOX6 (fluorouracil, oxaliplatin plus leucovorin) regimen and oral capecitabine for multiple metastases in a patient with primary nonurachal adenocarcinoma of urinary bladder is presented here as a strong support that the frontline chemotherapy for this infrequent malignant disease is just like what could be chosen for colorectal cancer.
机译:仔细的形态和免疫组织化学研究可以对涉及膀胱的转移性病变进行准确鉴别膀胱原发性腺癌,尤其是结肠中产生的癌症,但尚无关于医疗肿瘤医学家中泌尿膀胱晚期腺癌的标准化疗的共识。对修饰的folfox6(氟葡萄嘧啶,oxaliplatin plus Leucovorin)方案和口服葡萄球菌的持续反应在此作为泌尿膀胱原发性羽毛腺癌的患者中的多种转移作为一种强烈的支持,即这种不常见的恶性疾病的前线化学疗法就像可能选择结直肠癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号